Key Takeaways
- Cagrilintide—not “cagrilinitide”—is the published name of the investigational long-acting amylin analogue also called AM833.
- Amylin is a pancreatic peptide hormone involved in meal-related satiation, gastric emptying, and post-meal glucagon regulation.
- CagriSema is the research combination of cagrilintide and the GLP-1 receptor agonist semaglutide.
- REDEFINE 1 and REDEFINE 2 were large 68-week phase 3a trials; their abstracts report group-level outcomes in broad adult populations.
- A July 2026 post hoc analysis adds anthropometric context but cannot replace a prespecified trial designed around those questions.
- The major published abstracts do not establish a menopause-specific response or a unique outcome for women over 40.
- This article is research education only and does not provide medical or human-use guidance.
Cagrilintide research examines a long-acting amylin analogue alone and alongside semaglutide in CagriSema. The evidence now includes receptor pharmacology, early clinical studies, two large phase 3a REDEFINE trials, and a 2026 secondary analysis. Together, these sources show why amylin and GLP-1 pathways are being studied in combination. They do not establish a special result for women over 40, a menopause-specific effect, or a personal-use recommendation.
Research boundary: This article is for research and educational purposes only. Luvi Science compounds are for laboratory and research use only, not for human or veterinary use. This is not medical advice and includes no dosing, route, administration, treatment, efficacy, or safety guidance.
What Is Cagrilintide?
Cagrilintide is a lipid-modified analogue of amylin developed under the research code AM833. “Long-acting” describes its engineered pharmacokinetic profile relative to native amylin; it does not imply greater effectiveness or suitability for any person. A 2021 pharmacology study tested AM833 across receptor-binding, activation, and regulation measures and described activity at amylin receptors and the calcitonin receptor.
The spelling matters. PubMed-indexed trials, reviews, and pharmacology papers use cagrilintide. The extra syllable in “cagrilinitide” is a common search and editorial error. Using the published name improves literature retrieval and reduces the chance of missing authoritative records.
What is an amylin analogue?
An analogue is a modified molecule designed to retain selected biological activity while changing characteristics such as stability or duration. An amylin analogue is therefore not native amylin. It is an engineered peptide studied against the same receptor family or physiological pathway.
Understanding Amylin Biology
Where amylin comes from
Amylin, also called islet amyloid polypeptide or IAPP, is co-secreted with insulin by pancreatic beta cells. A 2026 review in Pharmacological Research summarizes its roles in post-meal glucose regulation, gastric emptying, glucagon secretion, and central satiation signalling. Those are normal physiological functions, not proof that an analogue will reproduce every native effect or produce a particular clinical outcome.
How amylin receptors are organized
Amylin receptors belong to the calcitonin-family receptor system. They are formed when the calcitonin receptor associates with receptor activity-modifying proteins, or RAMPs. Different receptor complexes can produce different pharmacological profiles. The AM833 study is useful because it compares multiple receptor endpoints instead of reducing cagrilintide to a single simplified target.
Why combine amylin and GLP-1 research?
Amylin-family and GLP-1 signalling overlap in broad metabolic research questions but are not interchangeable. Investigators study the combination because distinct receptor systems may produce complementary group-level effects. That is a research rationale, not evidence that “two pathways are always better” or that every observed result is additive.
Cagrilintide, Semaglutide, and CagriSema Compared
| Research feature | Cagrilintide | Semaglutide | CagriSema |
|---|---|---|---|
| Primary pathway | Amylin/calcitonin-family receptor pharmacology | GLP-1 receptor signalling | Both components studied together |
| Identity | Long-acting amylin analogue; AM833 | GLP-1 receptor agonist | Research combination, not a new single peptide |
| Evidence discussed here | Receptor study and phase 2 trial | Active comparator/component in combination trials | Phase 1b, phase 2, and phase 3a trials |
| What cannot be assumed | That native-amylin findings all transfer to the analogue | That GLP-1 findings describe amylin pharmacology | That the combination has a menopause-specific effect |
For context on other multi-receptor programs, Luvi’s GLP-1, GIP, and triple-agonist comparison explains why receptor labels should be kept distinct. The retatrutide research guide covers a different investigational molecule and should not be used as evidence about cagrilintide.
What the Clinical Research Shows
Early studies established feasibility, not certainty
A phase 1b study published in 2021 enrolled 96 participants and focused primarily on safety, tolerability, and pharmacokinetics of the cagrilintide-semaglutide combination. A separate phase 2 cagrilintide study randomized 706 participants to multiple cagrilintide groups, an active comparator, or placebo for 26 weeks. The paper reported greater mean percentage body-weight changes across cagrilintide groups than placebo, with gastrointestinal events among the most frequent adverse events. These studies helped justify larger trials; they were not the final word on long-term outcomes or population-specific effects.
REDEFINE 1
The 2025 REDEFINE 1 publication describes a 68-week, multicentre, double-blind phase 3a trial in 3,417 adults without diabetes who had obesity or overweight with at least one related condition. Participants were assigned to CagriSema, either component alone, or placebo. In the treatment-policy analysis, the estimated mean body-weight change was −20.4% in the CagriSema group and −3.0% with placebo. Gastrointestinal adverse events were reported in 79.6% and 39.9% of those groups, respectively, and were described as mainly transient and mild to moderate.
Those are group-level trial results under a defined protocol. They do not predict an individual outcome, establish comparative benefit for every subgroup, or answer questions the trial was not designed to test. The study was funded by Novo Nordisk, which should be considered when evaluating the evidence alongside design, reporting, and independent replication.
REDEFINE 2
REDEFINE 2 enrolled 1,206 adults with overweight or obesity and type 2 diabetes. At week 68, the abstract reports an estimated mean body-weight change of −13.7% with CagriSema and −3.4% with placebo. It also reports glycemic outcomes and gastrointestinal adverse-event rates of 72.5% and 34.4%, respectively. Because the population and clinical context differ from REDEFINE 1, the numerical results should not be pooled informally or transferred to people outside the study criteria.
What the 2026 post hoc analysis adds
A July 2026 secondary, post hoc analysis of REDEFINE 1 examined body-mass index and waist-to-height-ratio targets alongside percentage change. It reported that 30.3% of the CagriSema group met both specified anthropometric targets at week 68, compared with 19.1% for semaglutide, 9.0% for cagrilintide, and 3.3% for placebo. Because these were secondary post hoc analyses, they are best read as additional context and hypothesis development—not as a replacement for prespecified primary outcomes or a new standalone trial.
Why Women Over 40 Should Read the Evidence Carefully
Luvi Science serves many women over 40 who encounter metabolic-research headlines. That makes evidence literacy especially relevant, but it does not justify creating a women-specific claim where the publications do not provide one. Age, sex, body composition, menopausal stage, diabetes status, and background health can all matter to study interpretation. The major abstracts cited here describe broad adult eligibility criteria and aggregate results; they do not establish a unique CagriSema response for perimenopausal or postmenopausal women.
What the current papers can answer
- How cagrilintide is classified and which receptors researchers investigate;
- how the major trials were designed, how large they were, and which group-level endpoints they reported;
- which common adverse-event categories appeared in the published abstracts; and
- which questions were primary, secondary, or post hoc.
What they cannot answer
- Whether menopausal stage changes response;
- whether a woman over 40 should use an investigational compound;
- how individual benefits and risks compare; or
- what dose, route, schedule, or administration approach should be used.
For a broader, non-prescriptive foundation, read Luvi’s GLP-1 research overview for women and evidence guide to GLP-1 wellness research. The newer GLP-1 receptor and skin-biology review also demonstrates why receptor presence, mechanism, and clinical outcome must be treated as separate evidence layers.
How to Evaluate Emerging Cagrilintide Claims
| Question | Strong evidence signal | Warning sign |
|---|---|---|
| Is the compound identified correctly? | Published name, study code, and source citation agree | Misspelled names or mixed compound identities |
| What evidence layer is cited? | Receptor, animal, early-phase, and phase 3 findings are separated | Mechanism is presented as a guaranteed outcome |
| Was the analysis prespecified? | Primary and secondary outcomes are labelled accurately | Post hoc findings are presented as confirmatory |
| Does the claim concern women over 40? | A dedicated or prespecified subgroup analysis is available | Mixed-adult results are rewritten as menopause-specific |
| Are limitations visible? | Population, duration, adverse events, funding, and uncertainty appear beside results | Only the largest positive number is quoted |
The Luvi weight-management research Q&A provides additional definitions, while the Peptide Library can help readers keep compound identities and evidence categories separate.
Key Terms and Definitions
- Amylin
- A pancreatic peptide hormone, also called IAPP, co-secreted with insulin and studied in meal-related metabolic signalling.
- Cagrilintide
- An investigational long-acting amylin analogue also known by the research code AM833.
- CagriSema
- The research combination of cagrilintide and semaglutide.
- GLP-1 receptor agonist
- A molecule that activates the GLP-1 receptor; semaglutide is the GLP-1 component studied in CagriSema.
- Phase 3a trial
- A late-stage clinical study designed to evaluate predefined efficacy and safety outcomes in a larger population.
- Post hoc analysis
- An analysis planned or conducted after the original trial design; useful for exploration but generally less confirmatory than a prespecified primary analysis.
Frequently Asked Questions About Cagrilintide Research
What is cagrilintide?
Cagrilintide, also called AM833, is an investigational long-acting analogue of the pancreatic peptide hormone amylin. It has been studied alone and with semaglutide in the combination called CagriSema.
What is CagriSema?
CagriSema is the research name for coadministered cagrilintide and semaglutide. It combines amylin-family and GLP-1 receptor signalling in one clinical research program.
What does amylin do?
Amylin is co-secreted with insulin by pancreatic beta cells. Research links it to meal-related satiation, slower gastric emptying, and reduced post-meal glucagon secretion.
How is cagrilintide different from semaglutide?
Cagrilintide acts through calcitonin-family receptors, including amylin receptors, while semaglutide is a GLP-1 receptor agonist. Their targets and evidence bases are different even when they are studied together.
What did REDEFINE 1 study?
REDEFINE 1 was a 68-week phase 3a trial in 3,417 adults with overweight plus a related condition or obesity and without diabetes. It compared CagriSema, each component alone, and placebo.
What did REDEFINE 2 study?
REDEFINE 2 was a 68-week phase 3a trial in 1,206 adults with overweight or obesity and type 2 diabetes. It compared CagriSema with placebo and assessed body-weight, glycemic, and safety outcomes.
Is cagrilintide research specific to women over 40?
No. The major published abstracts describe broad adult study populations, not a menopause-specific trial. They do not establish a unique benefit, risk, or response for women over 40.
Does menopause research prove cagrilintide works differently?
No. The cited cagrilintide trials do not establish a menopause-specific effect. Questions about age, sex, body composition, and menopausal stage require prespecified subgroup analyses or dedicated studies.
Is cagrilintide the same as pramlintide?
No. Both are amylin analogues, but they are different molecules with different pharmacology and development histories. Findings about one should not automatically be assigned to the other.
Can this article be used as medical or human-use guidance?
No. This article is research education only. It provides no dosing, route, administration, treatment, efficacy, or safety instructions and is not intended for human or veterinary use.
Sources
- AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors. PMID 33727283.
- Once-weekly cagrilintide for weight management: phase 2 dose-finding trial. PMID 34798060.
- Cagrilintide with semaglutide: randomized phase 1b trial. PMID 33894838.
- Coadministered cagrilintide and semaglutide in type 2 diabetes: phase 2 trial. PMID 37364590.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). PMID 40544433.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). PMID 40544432.
- Secondary, post hoc anthropometric analysis of REDEFINE 1. PMID 42503495.
- Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs. PMID 42586227.
Continue Exploring Metabolic Research
Use the linked papers to distinguish receptor pharmacology, early trials, phase 3 results, and secondary analyses. Continue with the Luvi Science Peptide Library or browse the Luvi Science research catalog. Catalog access does not imply a dose, route, administration method, treatment, expected outcome, or suitability for human use.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. Luvi Science does not provide dosing, route, administration, treatment, efficacy, or safety guidance.